Eli Lilly raising GLP-1 prices abroad raises more questions about US pricing: BofA analyst

Eli Lilly (LLY) has raised the price of its GLP-1 weight-loss injectable, Zepbound, in the UK from approximately $125 to $165, with plans for additional hikes and similar actions across other European countries. This move is a direct response to President Trump's 'Most Favored Nations' pricing initiative, aimed at normalizing global drug costs. While LLY stock was up 1%, Bank of America analysts question the effective impact on European consumers due to prevalent out-of-pocket spending markets, and anticipate that this strategy is unlikely to result in lower US drug prices or significant P&L risk for Lilly.

Analysis

Eli Lilly (LLY) has initiated a significant price increase for its GLP-1 injectable, Zepbound, in the United Kingdom, raising its cost from approximately $125 to $165 with further hikes planned. This strategic adjustment, set to be replicated in other European nations, is a direct response to the 'Most Favored Nations' pricing policy advocated by President Trump, which seeks to align US drug prices with lower international benchmarks. While LLY's stock saw a 1% increase following the announcement, analyst commentary from Bank of America raises questions about the tangible impact of these price changes. The analyst notes that many European markets for GLP-1s operate on an out-of-pocket basis, meaning government price agreements are not in place, which could limit the scope of who is affected by the new pricing. Crucially, this analysis suggests that Lilly's actions in Europe are unlikely to compel significant price cuts in the more lucrative US market, thus protecting the company's profit and loss outlook from material risk.

Key Decisions for Investors

• Investors may view Lilly's proactive European price hikes as a shrewd defensive maneuver that mitigates political risk from the US while likely protecting its high-margin American market, reinforcing the long-term bullish thesis for the stock.
• Monitor for any signs that European governments are pushing back or establishing formal price negotiations for GLP-1s, as this could alter the effectiveness of Lilly's current strategy and introduce new revenue headwinds.
• Consider that while this move appears to neutralize a specific political threat without immediate P&L damage, the broader debate around US drug pricing remains a key long-term risk factor for Lilly and the pharmaceutical sector.